Improvement of cerebral blood flow by olprinone, a phosphodiesterase-3 inhibitor, in mild heart failure.

Abstract

Cerebral blood flow (CBF) is reduced in heart failure (HF). For the treatment of acute HF, a phosphodiesterase-3 inhibitor, olprinone (OL), yields an increase in myocardial contractility and a decrease in arterial afterload. During a 15-min intravenous infusion of OL (0.2 microg/kg/min), regional CBF at 6 sites of each cerebral cortex was examined using technetium-99m-ethylcysteinate dimer brain SPECT in 18 HF patients and 7 age-matched normal subjects. The baseline CBF was significantly reduced in HF (43.0 +/- 3.9 ml/min/100 g) compared to that in normal subjects (48.0 +/- 4.6 ml/min/100 g, p < 0.01). The baseline CBF showed a significant negative correlation with the increase in CBF during the OL infusion in HF (r = -0.38, p < 0.01) and normal subjects (r = -0.65, p < 0.01). The percent increase in CBF was significantly greater in HF (13.7%) than in normal subjects (9.8%, p < 0.046). In patients with HF, the CBF of the cerebral cortex was decreased, but was increased by OL infusion.

• Authors: Takashi Ueda, Katsufumi Mizushige, Kazushi Yukiiri, Tsutomu Takahashi, Masakazu Kohno
• Journal: Cerebrovascular diseases (Basel, Switzerland) (Cerebrovasc Dis) Vol. 16 Issue 4 Pg. 396-401 ( 2003) ISSN: 1015-9770 [Print] Switzerland
• PMID: 13130181 (Publication Type: Clinical Trial, Journal Article)
• Copyright: Copyright 2003 S. Karger AG, Basel

Chemical References

• Imidazoles
• Phosphodiesterase Inhibitors
• Pyridones
• olprinone

Topics

• Aged
• Aged, 80 and over
• Blood Pressure (drug effects)
• Cerebral Cortex (blood supply, diagnostic imaging, drug effects)
• Cerebrovascular Circulation (drug effects)
• Female
• Heart Failure (diagnostic imaging, physiopathology)
• Heart Rate (drug effects)
• Humans
• Imidazoles (pharmacology)
• Male
• Middle Aged
• Phosphodiesterase Inhibitors (pharmacology)
• Pyridones (pharmacology)
• Radionuclide Imaging
• Severity of Illness Index